as for remetti, it was bad, he made it good, by the end things were slowing a bit. palmasno came in, turned it around, and by the end of his tenure turned it over to remetti, they have the same kind of arc to her career there. >> david i want to talk about something earlier we talked about. that is the volume of deals we are hearing about as you work your sources. already this year, proposed but not completed. pfizer, astrazeneca, not even accepted. time warner cable and there are others. why are deals heating up as much? what are you hearing and where will the deals likely be for the rest of this year? >> you know, tyler that is a great question, of course. and you're right? we have been waiting for a wave of m & a for years and it has not really come, given the extraordinarily low year for borrowing costs. the stock price goes up, and you know, relatively strong equity markets certainly if you want to use your currency yet very few deals until now. i can tell you until speaking to the bankers and lawyers and other people who work on these transactions they're as b